Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
Researchers sought to determine whether interleukin-6 levels would be predictive of survival in patients with Hodgkin lymphoma receiving nivolumab.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
The combination continued to best CHOP at 5 years.
Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.
Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.
Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.
The median duration of response was 31.6 months, and the median duration of complete response was not reached.
The median age of trial participants was 3.8 years younger than the median age of the real-world population.
The median duration of response was not reached, and responses deepened over time.
More than two-thirds of patients studied did not undergo biomarker testing.
Increasing karyotypic complexity was an independent predictor of shorter progression-free and overall survival.
The approval was based on data from the phase 3 ASPEN trial.
Undetectable MRD was not associated with significantly better PFS at any time point.
The excess risk of cardiovascular disease from involved-field radiotherapy was 6.2%.
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Responses improved over time, and the best overall response rate was 85%.
Researchers sought to determine whether patients with lymphoma would develop antibodies with a COVID-19 vaccine 6 months after treatment with anti-CD20-containing therapy.
Lymphoma patients displayed cognitive decline 6 months after chemotherapy, both by objective assessment and self-report.
CHIP was associated with higher rates of complete response and cytokine release syndrome.